EP0543871A1 - Composition de doxorubicine/liposome stable - Google Patents

Composition de doxorubicine/liposome stable

Info

Publication number
EP0543871A1
EP0543871A1 EP91914508A EP91914508A EP0543871A1 EP 0543871 A1 EP0543871 A1 EP 0543871A1 EP 91914508 A EP91914508 A EP 91914508A EP 91914508 A EP91914508 A EP 91914508A EP 0543871 A1 EP0543871 A1 EP 0543871A1
Authority
EP
European Patent Office
Prior art keywords
doxorubicin
composition
suspension
mole percent
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP91914508A
Other languages
German (de)
English (en)
Inventor
Anthony Hei-Leung Huang
Robert Abra
Richard E. Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liposome Technology Inc
Original Assignee
Liposome Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liposome Technology Inc filed Critical Liposome Technology Inc
Publication of EP0543871A1 publication Critical patent/EP0543871A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Composition de doxorubicine/lipide lyophilisée ne souffrant pas de la dégradation de la doxorubicine lors du stockage. La composition est formée par lyophilisation d'une suspension de liposomes de doxorubicine ayant un pH compris entre 3,0 et 4,4.
EP91914508A 1990-08-08 1991-08-02 Composition de doxorubicine/liposome stable Ceased EP0543871A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56407090A 1990-08-08 1990-08-08
US564070 1990-08-08

Publications (1)

Publication Number Publication Date
EP0543871A1 true EP0543871A1 (fr) 1993-06-02

Family

ID=24253045

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91914508A Ceased EP0543871A1 (fr) 1990-08-08 1991-08-02 Composition de doxorubicine/liposome stable

Country Status (5)

Country Link
EP (1) EP0543871A1 (fr)
JP (1) JPH06502623A (fr)
AU (1) AU8329391A (fr)
CA (1) CA2088975A1 (fr)
WO (1) WO1992002208A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU700833B2 (en) * 1991-12-02 1999-01-14 Merial Medicinal products and pure preparations of melarsomine dihydrochloride, process for obtaining them and intermediate products obtained

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1006379A3 (fr) * 1992-11-26 1994-08-09 Raymond Gilles Procede de conservation de cellules vivantes, d'ensembles de cellules et/ou de derives de ces cellules par lyophilisation.
ES2072223B1 (es) * 1993-11-25 1996-03-16 Lipotec Sa Liposomas encapsulando doxorubicina.
ES2186484B1 (es) 2000-10-10 2004-07-01 Lipotec, S.A. Liposomas encapsulando farmacos anticancerosos y uso de los mismos en el tratamiento de tumores malignos.
WO2008040556A1 (fr) 2006-10-06 2008-04-10 Scil Technology Gmbh Formation de vésicules reconstituées séchées pour application pharmaceutique
PL226015B1 (pl) 2011-03-03 2017-06-30 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Liposomowy preparat zawierajacy przeciwnowotworowa substancje aktywna, sposob jego wytwarzania i zawierajaca go kompozycja farmaceutyczna

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4927571A (en) * 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9202208A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU700833B2 (en) * 1991-12-02 1999-01-14 Merial Medicinal products and pure preparations of melarsomine dihydrochloride, process for obtaining them and intermediate products obtained

Also Published As

Publication number Publication date
CA2088975A1 (fr) 1992-02-09
AU8329391A (en) 1992-03-02
WO1992002208A1 (fr) 1992-02-20
JPH06502623A (ja) 1994-03-24

Similar Documents

Publication Publication Date Title
US4927571A (en) Preparation of injectable doxorubicin/liposome suspension
US5100591A (en) Process for preparing lipid microparticles
US4766046A (en) Stabilized liposome/amphotericin composition and method
JP2958774B2 (ja) アンホテリシンｂリポソームの改良調整法
US4857319A (en) Method for preserving liposomes
US5194266A (en) Amphotericin B/cholesterol sulfate composition and method
EP0437479B1 (fr) Procede de fabrication de liposomes a stabilite amelioree pendant le sechage
US5000959A (en) Liposome composition and production thereof
CA2505520C (fr) Preparations liposomales d'agents pharmaceutiques stabilisees par des proteines
EP3142656B1 (fr) Formulations de liposomes multivésiculaires d'acide tranexamique
CA2221341C (fr) Suspensions liposomales submicroniques obtenues a partir de lyophilisats preliposomaux
EP0303683B1 (fr) Procede et composition de sulfate de cholesterol/amphotericine b
HU203278B (en) Process for producing compositions containing liposomes
US5032582A (en) Method for treating fungal infections with amphotericin B/cholesterol sulfate composition
US6060080A (en) Liposomal products
US5080904A (en) Liposome composition and its production
CN104000783A (zh) 头孢喹肟脂质体
CA2705031A1 (fr) Compositions de liposomes stabilises par un gel, leurs procedes de preparation et leurs utilisations
US20060030578A1 (en) Pharmaceutically active lipid based formulation of irinotecan
US5180713A (en) Stabilized liposome/amphotercin B composition and method
EP0543871A1 (fr) Composition de doxorubicine/liposome stable
US20040175417A1 (en) Amphotericin B liposome preparation
JPH0114A (ja) リポソーム製剤およびその製造法
WO1993023016A1 (fr) Formulations de liposomes contenant des rifamycines
KR20020011993A (ko) 미소한 리포좀 및 그 제조 방법

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930304

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19930810

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19940129